vs
Realty Income（O）与百利高（PRGO）财务数据对比。点击上方公司名可切换其他公司
Realty Income的季度营收约是百利高的1.3倍（$1.5B vs $1.1B），Realty Income净利率更高（19.9% vs -127.8%，领先147.7%），Realty Income同比增速更快（11.0% vs -2.5%），Realty Income自由现金流更多（$1.2B vs $148.6M），过去两年Realty Income的营收复合增速更高（8.6% vs 1.3%）
Realty Income是一家房地产投资信托企业，投资范围覆盖美国、英国及欧洲其他六个国家的独立单租户商业地产，旗下物业普遍采用三重净租约模式。公司注册地为美国马里兰州，总部位于加利福尼亚州圣迭戈市。
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
O vs PRGO — 直观对比
营收规模更大
O
是对方的1.3倍
$1.1B
营收增速更快
O
高出13.5%
-2.5%
净利率更高
O
高出147.7%
-127.8%
自由现金流更多
O
多$1.0B
$148.6M
两年增速更快
O
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $1.1B |
| 净利润 | $296.1M | $-1.4B |
| 毛利率 | — | 32.6% |
| 营业利润率 | 21.7% | -116.0% |
| 净利率 | 19.9% | -127.8% |
| 营收同比 | 11.0% | -2.5% |
| 净利润同比 | 48.3% | -3093.9% |
| 每股收益（稀释后） | $0.32 | $-10.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPRGO
| Q4 25 | $1.5B | $1.1B | ||
| Q3 25 | $1.5B | $1.0B | ||
| Q2 25 | $1.4B | $1.1B | ||
| Q1 25 | $1.4B | $1.0B | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $1.3B | $1.1B | ||
| Q1 24 | $1.3B | $1.1B |
净利润OPRGO
| Q4 25 | $296.1M | $-1.4B | ||
| Q3 25 | $315.8M | $7.5M | ||
| Q2 25 | $196.9M | $-8.4M | ||
| Q1 25 | $249.8M | $-6.4M | ||
| Q4 24 | $199.6M | $-44.4M | ||
| Q3 24 | $269.5M | $-21.0M | ||
| Q2 24 | $259.4M | $-108.4M | ||
| Q1 24 | $132.3M | $2.0M |
毛利率OPRGO
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 33.1% |
营业利润率OPRGO
| Q4 25 | 21.7% | -116.0% | ||
| Q3 25 | 23.2% | 7.0% | ||
| Q2 25 | 15.8% | 4.3% | ||
| Q1 25 | 19.3% | 4.5% | ||
| Q4 24 | 16.5% | 10.0% | ||
| Q3 24 | 21.5% | 7.4% | ||
| Q2 24 | 20.7% | -2.5% | ||
| Q1 24 | 11.9% | -5.1% |
净利率OPRGO
| Q4 25 | 19.9% | -127.8% | ||
| Q3 25 | 21.5% | 0.7% | ||
| Q2 25 | 14.0% | -0.8% | ||
| Q1 25 | 18.1% | -0.6% | ||
| Q4 24 | 14.9% | -3.9% | ||
| Q3 24 | 20.2% | -1.9% | ||
| Q2 24 | 19.4% | -10.2% | ||
| Q1 24 | 10.5% | 0.2% |
每股收益（稀释后）OPRGO
| Q4 25 | $0.32 | $-10.23 | ||
| Q3 25 | $0.35 | $0.05 | ||
| Q2 25 | $0.22 | $-0.06 | ||
| Q1 25 | $0.28 | $-0.05 | ||
| Q4 24 | $0.23 | $-0.32 | ||
| Q3 24 | $0.30 | $-0.15 | ||
| Q2 24 | $0.29 | $-0.79 | ||
| Q1 24 | $0.16 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $434.8M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $39.4B | $2.9B |
| 总资产 | $72.8B | $8.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OPRGO
| Q4 25 | $434.8M | — | ||
| Q3 25 | $417.2M | $432.1M | ||
| Q2 25 | $800.4M | $454.2M | ||
| Q1 25 | $319.0M | $409.9M | ||
| Q4 24 | $445.0M | $558.8M | ||
| Q3 24 | $397.0M | $1.5B | ||
| Q2 24 | $442.8M | $542.8M | ||
| Q1 24 | $680.2M | $658.5M |
股东权益OPRGO
| Q4 25 | $39.4B | $2.9B | ||
| Q3 25 | $39.1B | $4.4B | ||
| Q2 25 | $39.2B | $4.5B | ||
| Q1 25 | $39.0B | $4.4B | ||
| Q4 24 | $38.8B | $4.3B | ||
| Q3 24 | $38.5B | $4.6B | ||
| Q2 24 | $38.6B | $4.5B | ||
| Q1 24 | $39.0B | $4.7B |
总资产OPRGO
| Q4 25 | $72.8B | $8.5B | ||
| Q3 25 | $71.3B | $10.1B | ||
| Q2 25 | $71.4B | $10.1B | ||
| Q1 25 | $69.8B | $9.8B | ||
| Q4 24 | $68.8B | $9.6B | ||
| Q3 24 | $68.5B | $11.2B | ||
| Q2 24 | $68.1B | $10.4B | ||
| Q1 24 | $68.3B | $10.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.2B | $175.4M |
| 自由现金流经营现金流 - 资本支出 | $1.2B | $148.6M |
| 自由现金流率自由现金流/营收 | 77.6% | 13.4% |
| 资本支出强度资本支出/营收 | 3.3% | 2.4% |
| 现金转化率经营现金流/净利润 | 4.06× | — |
| 过去12个月自由现金流最近4个季度 | $3.9B | $145.1M |
8季度趋势，按日历期对齐
经营现金流OPRGO
| Q4 25 | $1.2B | $175.4M | ||
| Q3 25 | $943.1M | $51.7M | ||
| Q2 25 | $1.1B | $75.9M | ||
| Q1 25 | $787.5M | $-64.5M | ||
| Q4 24 | $972.0M | $312.6M | ||
| Q3 24 | $841.5M | $42.2M | ||
| Q2 24 | $981.2M | $9.5M | ||
| Q1 24 | $778.7M | $-1.4M |
自由现金流OPRGO
| Q4 25 | $1.2B | $148.6M | ||
| Q3 25 | $909.9M | $29.8M | ||
| Q2 25 | $1.0B | $56.7M | ||
| Q1 25 | $764.6M | $-90.0M | ||
| Q4 24 | $935.8M | $274.9M | ||
| Q3 24 | $807.9M | $15.1M | ||
| Q2 24 | $939.2M | $-18.9M | ||
| Q1 24 | $769.0M | $-26.5M |
自由现金流率OPRGO
| Q4 25 | 77.6% | 13.4% | ||
| Q3 25 | 61.9% | 2.9% | ||
| Q2 25 | 73.3% | 5.4% | ||
| Q1 25 | 55.4% | -8.6% | ||
| Q4 24 | 69.8% | 24.2% | ||
| Q3 24 | 60.7% | 1.4% | ||
| Q2 24 | 70.1% | -1.8% | ||
| Q1 24 | 61.0% | -2.4% |
资本支出强度OPRGO
| Q4 25 | 3.3% | 2.4% | ||
| Q3 25 | 2.3% | 2.1% | ||
| Q2 25 | 1.9% | 1.8% | ||
| Q1 25 | 1.7% | 2.4% | ||
| Q4 24 | 2.7% | 3.3% | ||
| Q3 24 | 2.5% | 2.5% | ||
| Q2 24 | 3.1% | 2.7% | ||
| Q1 24 | 0.8% | 2.3% |
现金转化率OPRGO
| Q4 25 | 4.06× | — | ||
| Q3 25 | 2.99× | 6.89× | ||
| Q2 25 | 5.39× | — | ||
| Q1 25 | 3.15× | — | ||
| Q4 24 | 4.87× | — | ||
| Q3 24 | 3.12× | — | ||
| Q2 24 | 3.78× | — | ||
| Q1 24 | 5.89× | -0.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
O
| Product And Service Retail | $900.8M | 61% |
| Other | $531.5M | 36% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
